Cambridge Investment Research Advisors’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $59K | Hold |
41,873
| – | – | ﹤0.01% | 3522 |
|
|
2025
Q1 | $64K | Hold |
41,873
| – | – | ﹤0.01% | 3390 |
|
|
2024
Q4 | $104K | Hold |
41,873
| – | – | ﹤0.01% | 3324 |
|
|
2024
Q3 | $48K | Hold |
41,873
| – | – | ﹤0.01% | 3334 |
|
|
2024
Q2 | $46K | Hold |
41,873
| – | – | ﹤0.01% | 3222 |
|
|
2024
Q1 | $52K | Hold |
41,873
| – | – | ﹤0.01% | 3208 |
|
|
2023
Q4 | $44K | Buy |
41,873
+26,535
| +173% | +$27.9K | ﹤0.01% | 3107 |
|
|
2023
Q3 | $105K | Hold |
15,338
| – | – | ﹤0.01% | 2956 |
|
|
2023
Q2 | $159K | Hold |
15,338
| – | – | ﹤0.01% | 2936 |
|
|
2023
Q1 | $124K | Hold |
15,338
| – | – | ﹤0.01% | 2927 |
|
|
2022
Q4 | $242K | Sell |
15,338
-200
| -1% | -$3.16K | ﹤0.01% | 2600 |
|
|
2022
Q3 | $245K | Buy |
15,538
+200
| +1% | +$3.15K | ﹤0.01% | 2535 |
|
|
2022
Q2 | $214K | Hold |
15,338
| – | – | ﹤0.01% | 2677 |
|
|
2022
Q1 | $264K | Hold |
15,338
| – | – | ﹤0.01% | 2650 |
|
|
2021
Q4 | $223K | Hold |
15,338
| – | – | ﹤0.01% | 2782 |
|
|
2021
Q3 | $276K | Buy |
15,338
+638
| +4% | +$11.5K | ﹤0.01% | 2529 |
|
|
2021
Q2 | $258K | Hold |
14,700
| – | – | ﹤0.01% | 2586 |
|
|
2021
Q1 | $370K | Sell |
14,700
-30,073
| -67% | -$757K | ﹤0.01% | 2131 |
|
|
2020
Q4 | $290K | Buy |
44,773
+73
| +0.2% | +$473 | ﹤0.01% | 2171 |
|
|
2020
Q3 | $115K | Hold |
44,700
| – | – | ﹤0.01% | 2373 |
|
|
2020
Q2 | $72K | Hold |
44,700
| – | – | ﹤0.01% | 2351 |
|
|
2020
Q1 | $46K | Hold |
44,700
| – | – | ﹤0.01% | 2185 |
|
|
2019
Q4 | $84K | Hold |
44,700
| – | – | ﹤0.01% | 2327 |
|
|
2019
Q3 | $48K | Buy |
+44,700
| New | +$48K | ﹤0.01% | 2283 |
|